RAPT Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• RAPT Therapeutics Inc RAPT.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -79 cents. The mean expectation of five analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -16 cents to -8 cents per share.

• Reported revenue was zero​; analysts expected zero.

• RAPT Therapeutics Inc's reported EPS for the quarter was a loss of 8 cents​.

• The company reported a quarterly loss of $17.17 million.

• RAPT Therapeutics Inc shares had fallen by 34.4% this quarter and lost 49.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for RAPT Therapeutics Inc is $4.00

This summary was machine generated from LSEG data May 8 at 02:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)